Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report) shares gapped up before the market opened on Thursday . The stock had previously closed at $7.32, but opened at $7.76. Valneva shares last traded at $8.06, with a volume of 281,588 shares traded.
Analysts Set New Price Targets
A number of equities analysts have weighed in on the company. HC Wainwright reiterated a "buy" rating and set a $17.00 price objective on shares of Valneva in a research note on Tuesday, April 15th. Guggenheim decreased their price target on Valneva from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, May 8th.
Read Our Latest Stock Analysis on Valneva
Valneva Price Performance
The stock has a market capitalization of $647.53 million, a PE ratio of -6.39 and a beta of 1.74. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.70 and a quick ratio of 2.12. The stock's fifty day moving average is $6.16 and its 200-day moving average is $6.36.
Valneva (NASDAQ:VALN - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.40) by $0.27. The firm had revenue of $51.79 million for the quarter, compared to analysts' expectations of $41.80 million. Valneva had a negative return on equity of 43.05% and a negative net margin of 43.08%. As a group, equities analysts predict that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Valneva
A hedge fund recently raised its stake in Valneva stock. Wells Fargo & Company MN lifted its stake in shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) by 14.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 246,766 shares of the company's stock after purchasing an additional 30,859 shares during the period. Wells Fargo & Company MN owned about 0.30% of Valneva worth $1,079,000 as of its most recent filing with the Securities & Exchange Commission. 11.39% of the stock is owned by hedge funds and other institutional investors.
About Valneva
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Articles
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access